Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Table 2

Baseline metabolic indices in the intent-to-treat (ITT) population. The sample sizes for variables are less than the full ITT population (𝑛=5603), due to lack of data.

	Means ± SD; (mmol/L)
Fasting plasma glucose (𝑛=2551)	6.8 ± 2.1
Triglycerides (𝑛=2288)	2.4 ± 1.1
Cholesterol (𝑛=2305)	5.8 ± 1.1
HDL-cholesterol (𝑛=1893)	1.2 ± 0.5
LDL-cholesterol (𝑛=1421)	3.5 ± 1.1
Creatinine (𝑛=1952)	0.09 ± 0.06
Urinary albumin (𝑛=272)	92.7 ± 191.6